Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vitreous Hemorrhage

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Vitreous Hemorrhage. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2009-015559-25 Sponsor Protocol Number: KCH1724 Start Date*: 2010-04-22
    Sponsor Name:King's College Hospital NHS Foundation Trust
    Full Title: Preoperative intravitreal ranibizumab for persistent diabetic vitreous haemorrhage: A randomized, double-masked, controlled study
    Medical condition: Retinopathy is a well recognised complication of diabetes and is a leading cause of vision loss in this patient group. The severity of diabetic retinopathy varies, but in its most severe form (pro...
    Disease: Version SOC Term Classification Code Term Level
    12. 10047655 Vitreous Haemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-003297-81 Sponsor Protocol Number: PDRPOZU1 Start Date*: 2011-09-12
    Sponsor Name:St Eriks Eye Hospital
    Full Title: A prospective, randomized study on intravitreal Ozurdex for preventing recurrent vitreous hemorrhage following pars plana vitrectomy for proliferative diabetic retinopathy
    Medical condition: Proliferative diabetic retinopathy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10036857 Proliferative diabetic retinopathy LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018919-16 Sponsor Protocol Number: TG-MV-010 Start Date*: 2010-06-28
    Sponsor Name:ThromboGenics NV
    Full Title: An Open-Label, Ascending- Exposure-Time, Single Center Trial to Evaluate the Pharmacokinetic Properties of Ocriplasmin (Generic Name of the Molecule Microplasmin) Intravitreal Injection in Subjects...
    Medical condition: Patients who require primary pars plana vitrectomy. A sample of vitreous will be taken at beginning of surgery for PK analysis.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10047644 Vitrectomy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001421-55 Sponsor Protocol Number: CRFB002GFR02 Start Date*: 2013-06-13
    Sponsor Name:Novartis Pharma S.A.S
    Full Title: An open-label Extended Clinical Protocol of ranibizumab to evaluate Safety and Efficacy in rare VEGF driven ocular diseases.
    Medical condition: Choroidal neovascularization not related to wet Age-related macular degeneration (wAMD), pathologic myopia (PM)or Pseudoxanthoma elasticum (PXE), as well as in Macular Edema (ME) not related to Ret...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10047060 Retina, choroid and vitreous haemorrhages and vascular disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-018637-21 Sponsor Protocol Number: 1 Start Date*: 2013-11-20
    Sponsor Name:Universitätsklinikum Schleswig-Holstein UKSH
    Full Title: Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrha...
    Medical condition: exsudative age-related macular degeneration with acut submacular hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10055305 Macula lutea hemorrhage LLT
    16.1 100000004853 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-006085-42 Sponsor Protocol Number: TG-MV-004 Start Date*: 2007-01-24
    Sponsor Name:ThromboGenics Ltd.
    Full Title: A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding, Multicenter Trial of Microplasmin Intravitreal Injection for Non-Surgical PVD Induction for Treatment of ...
    Medical condition: Vitreomacular Traction Syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.1 10051065 Vitreomacular traction syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-005081-19 Sponsor Protocol Number: 1 Start Date*: 2014-07-10
    Sponsor Name:HOSPICES CIVILS DELYON
    Full Title: Phase II study evaluating the efficacy of aflibercept for the treatment of idiopathic choroidal neovascularization in young subjects: the INTUITION study
    Medical condition: idiopathic choroidal neovascularization
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000753-45 Sponsor Protocol Number: NAVIT-18 Start Date*: 2018-11-11
    Sponsor Name:NAVARRBIOMED-FUNDACION MIGUEL SERVET
    Full Title: Vitreretinal surgery with and without oral anticoagulants: surgical complications, visual results and perioperative thromboembolic events.
    Medical condition: Patients undergoing vitreoretinal surgery under treatment with oral anticoagulants
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003640-23 Sponsor Protocol Number: ECR-RET-2013-05 Start Date*: 2014-01-13
    Sponsor Name:AIBILI - Association for Innovation and Biomedical Research on Light and Image
    Full Title: Prospective, randomized, multicentre, open label, phase II / III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP ...
    Medical condition: Patients with type I or type II diabetes mellitus and high risk diabetic retinopathy.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10036857 Proliferative diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004626-93 Sponsor Protocol Number: TG-MV-002 Start Date*: 2006-12-19
    Sponsor Name:ThromboGenics N.V.
    Full Title: A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding Trial of Microplasmin Intravitreal Injection for Non-Surgical PVD Induction for Treatment of Diabetic Macu...
    Medical condition: Diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    8.1 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) NL (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005228-10 Sponsor Protocol Number: TG-MV-008 Start Date*: 2008-10-03
    Sponsor Name:ThromboGenics NV
    Full Title: An Open Label, Single Center Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion
    Medical condition: Focal vitreomacular adhesion
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051065 Vitreomacular traction syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001171-36 Sponsor Protocol Number: TG-MV-001 Start Date*: 2005-05-13
    Sponsor Name:ThromboGenics Ltd.
    Full Title: A Dose-Escalation Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy for Vitreomacular Traction Maculopathy
    Medical condition: Vitreomacular Traction Maculopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005601-22 Sponsor Protocol Number: poc1doxy Start Date*: 2008-03-27
    Sponsor Name:
    Full Title: Proof–of–concept study 1 (POC1): Evaluation of effect of doxycycline versus placebo on retinal function and posterior segment neovascularization in patients with severe non-proliferative or early ...
    Medical condition: Diabetic retinopathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012689 Diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014409-15 Sponsor Protocol Number: CRFB002DPT04T Start Date*: 2010-01-08
    Sponsor Name:AIBILI - Association for Innovation and Biomedical Research on Light and Image
    Full Title: Prospective, randomized, multicenter, open label phase II study to access efficacy and safety of Lucentis monotherapy (ranibizumab 0.5 mg intravitreal injections) compared with Lucentis plus panret...
    Medical condition: Proliferative Diabetic Retinopathy.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036857 Proliferative diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016760-36 Sponsor Protocol Number: CC-02-2009 Start Date*: 2010-02-05
    Sponsor Name:AIBILI
    Full Title: Prospective, randomized, open label phase II study to assess efficacy and safety of Macugen® (pegaptanib 0.3 mg intravitreal injections) plus panretinal photocoagulation (PRP) and PRP (monotherapy)...
    Medical condition: Proliferative Diabetic Retinopathy.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036857 Proliferative diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003243-37 Sponsor Protocol Number: Start Date*: 2017-11-02
    Sponsor Name:MUST Coordinating Centre, John Hopkins Bloomberg School of Public Health
    Full Title: Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial
    Medical condition: Uveitic macular oedema
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10002709 Anterior uveitis LLT
    22.1 10015919 - Eye disorders 10022557 Intermediate uveitis LLT
    20.1 100000004862 10036370 Posterior uveitis LLT
    20.0 10015919 - Eye disorders 10033687 Panuveitis LLT
    20.1 10015919 - Eye disorders 10058202 Cystoid macular oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2016-000304-29 Sponsor Protocol Number: Start Date*: 2016-04-05
    Sponsor Name:MUST Coordinating Centre, John Hopkins Bloomberg School of Public Health
    Full Title: Periocular and Intravitreal Corticosteroids for Uveitic Macular Edema (POINT) Trial
    Medical condition: Uveitic macular oedema
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000014995 10002709 Anterior uveitis LLT
    20.0 100000161411 10022557 Intermediate uveitis LLT
    20.0 100000014975 10033687 Panuveitis LLT
    20.0 100000015065 10036370 Posterior uveitis LLT
    20.0 10015919 - Eye disorders 10058202 Cystoid macular oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000642-35 Sponsor Protocol Number: HL217-201 Start Date*: 2019-09-19
    Sponsor Name:HANLIM PHARM CO., LTD
    Full Title: A phase IIa randomized, double-blind, multicentre study to evaluate safety and efficacy of HL217 topical ophthalmologic solution in the treatment of exudative Age-Related Macular Degeneration (AMD)
    Medical condition: AMD (age-related macular degeneration)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10068530 Macular degeneration progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003165-13 Sponsor Protocol Number: 03 Start Date*: 2007-02-15
    Sponsor Name:Dep. Ophthalmology, Medical University of Vienna
    Full Title: A randomized, double-masked study with intraocular Bevacizumab (Avastin®) compared with non-treatment control in patients with persistent diabetic macular edema or persistent active neovascularisat...
    Medical condition: persistent diabetic macular edema or persistent active neovascularisation following lasercoagulation
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012689 Diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001469-28 Sponsor Protocol Number: SA2008 Start Date*: 2009-06-17
    Sponsor Name:Dep. of Ophthalmology, Medical University of Vienna
    Full Title: A randomized, double-masked study with intraocular Bevacizumab (Avastin®) compared with intravitreal Ranibizumab (Lucentis®) in patients with persistent diabetic macular edema or persistent active ...
    Medical condition: persistent diabetic macula edema or persistent diabetic proliferative retinopathy after lasercoagulation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012689 Diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 07:35:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA